About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.
2018 Juristant Badge - MBHB_165
Juristat #4 Overall Rank

E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.
Subscribe to this blog's feed

Contact the Docs

Recent Posts

Disclaimer

  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.
Juristat_165
Juristat #8 Overall Rank

Pharma-50-transparent_216px_red

« Africa (Still) Depending on the Kindness of Strangers in Anti-AIDS Drug Pricing | Main | Invitrogen and Clontech Settle Lengthy Patent Litigation »

May 30, 2007

Novacea and Schering-Plough to Collaborate

    By Jason Derry --

02novacea Novacea, Inc. and Schering-Plough have announced an agreement to develop and commercialize Asentar®, which is currently in Phase III clinical trials for the treatment of prostate cancer.  Novacea is to receive an upfront payment of $60 million and $12 million in common stock.  Novacea may also receive up to $380 million in future royalty payments on sales of Asentar.  The Agreement is subject to clearance under the Hart-Scott-Rodino Antitrust Improvement Act.
Scheringplough

Posted at 09:19 PM in Licensing |

Comments

The comments to this entry are closed.

March 2025

Sun Mon Tue Wed Thu Fri Sat
            1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30 31          

Categories

Archives

More...